**Lord’s Mark Industries Limited** (formerly Kratos Energy & Infrastructure Limited) is a diversified Indian industrial conglomerate that has recently emerged from a comprehensive **Pre-Packaged Insolvency Resolution Process (PPIRP)**. Following a **100% creditor-approved Resolution Plan** in **July 2025**, the company executed a **Reverse Merger** with Lord’s Mark Industries Pvt. Ltd., transforming from a non-operational power consultancy into a high-growth platform focused on MedTech, Clean Energy, and Sustainable Infrastructure. --- ### **Strategic Corporate Restructuring & Capital Structure** The company’s recent transformation is anchored by a court-mandated restructuring designed to eliminate legacy liabilities and provide a clean slate for expansion. * **The Reverse Merger:** The strategic investor (Lord’s Mark Industries Pvt. Ltd.) merged into the listed entity with a share swap ratio of **1.25 shares** of the listed company (FV **₹10**) for every **1 share** held in the transferor company (FV **₹5**). * **Capital Expansion:** To facilitate massive industrial scaling, the **Authorized Capital** was increased from **₹5 Crore** to **₹800 Crore**. * **Liquidity & Funding:** The Monitoring Committee has approved a **Rights Issue** of up to **₹200 Crore** to fund immediate expansion once trading resumes on the **BSE**. * **Valuation Framework:** Due to historical trading inactivity, the company’s valuation was determined using a **95% weight** on the **Discounted Cash Flow (DCF)** method, reflecting its future earning potential over its negative Net Asset Value (NAV). * **Talent & Branding:** To attract top-tier leadership, an **ESOP pool** of **2%** of equity capital was established. The company also appointed cricketing legend **Rahul Dravid** as the Brand Ambassador for the MedTech division through **2027**. --- ### **MedTech & Diagnostics: The Primary Growth Engine** Operating under the **LordsMed** brand, this division is positioning itself as a global hub for medical supply chains, leveraging indigenous manufacturing and high-barrier regulatory licenses. #### **Diagnostic Innovation & Market Access** * **High-Risk Licensing:** Lord’s Mark is the **2nd company in India** and one of only **9 globally** licensed for specific high-risk medical devices. * **Proprietary Technology:** Holds an exclusive **IIT-Bombay** license with a projected **₹3,000 Crore** market potential. * **Global Certifications:** Facilities are **ISO 13485:2016**, **CE certified**, and **CDSCO** approved. * **Product Portfolio:** Includes over **30 registered brands** and **ICMR-approved** rapid kits. The **HIV 1&2 Self Test** (a **Class D** IVD device) received an export license in **January 2026** for Africa, Latin America, and Europe. #### **Renal Care & AI-Diagnostics** * **Renalyx Acquisition:** The company holds an **85% stake** in **Renalyx Health Systems**, which developed the world’s first **AI-based Smart Hemodialysis Machine**. * **Global Standing:** One of only **six brands globally** to hold **CE Marking** for dialysis systems. * **Preventive Tech:** Collaborating with **C-MET** to develop non-invasive, AI-driven diagnostic technologies. #### **Surgical & Orthopedic Expansion** * **US FDA Registration:** Secured registration for over **150 products** as of **January 2026**, including orthopedic braces, spinal supports, and post-surgical rehab products. * **Infrastructure:** Operates a specialized facility in **Silvassa** with 38 advanced stitching machines and coating units. --- ### **Clean Energy & Sustainable Infrastructure** The company leverages a B2G (Business to Government) model, partnering with state agencies and central ministries to execute large-scale utility projects. * **Green Hydrogen:** Partnered with **Greenzo Energy India Limited** to develop **60 MW** of green hydrogen capacity across four cities in Uttar Pradesh. * **Solar Highway Lighting:** Secured a mandate from **NHAI** for solar lighting at **104 locations** in the Vijayawada region. * **Rural Electrification:** Active partner in the **'SAUBHAGYA'** scheme and provider of RMS-based solar LED street lights. * **E-Mobility:** Manufacturing and commissioning infrastructure for **E-Rickshaws, E-Loaders, E-Bikes, and E-Buses**, supported by in-house **Lithium Ferro Phosphate (LFP)** battery production. --- ### **Specialized Paper & Industrial Divisions** The paper division provides a steady cash-flow base with a focus on high-volume government and defense contracts. * **Market Leadership:** India’s leader in **Computer Continuous Stationery**. * **Sustainability:** Uses **100% recycled paper** and soya-based inks to mitigate raw material costs, which typically account for **45-50%** of revenue. * **Key Clients:** **Indian Railways** (tickets), **India Post**, and the **Ministry of Defense** (stationery). * **Fire Safety:** Specialized vertical for the installation of firefighting equipment and passive fire protection. --- ### **Multi-State Investment Roadmap (2026-2027)** Following the **World Economic Forum 2026**, the company committed to a phased investment strategy: | State | Focus Area | Investment | Est. Annual Revenue | | :--- | :--- | :--- | :--- | | **Uttar Pradesh** | Green Hydrogen & Solar/BESS | **₹2,000 Crore** | **₹700-800 Crore** | | **Maharashtra** | Medical Devices & 5,000 Labs | **₹225 Crore** | **₹800 Crore** | | **Kerala** | Medical & Healthcare | **₹100 Crore** | **₹200 Crore** | | **Assam** | Medical Infrastructure | *Evaluating* | **₹200 Crore** | --- ### **Subsidiary Structure & Financial Transition** The company operates through five key subsidiaries to maintain operational focus: * **Lords Automotive Private Ltd** (**90%**) * **Lords Mark Biotech Private Ltd** (**75%**) * **Lords Mark Micro Biotech Private Ltd** (**92%**) * **Renalyxe Health Systems Private Ltd** (**85%**) * **Lords Green Energy Private Ltd** (**49%**) **Financial Reporting:** The company is transitioning to **Ind AS**, with a formal transition date of **April 1, 2028**. In the immediate post-merger period (Sept 2025), the Lord’s Mark subsidiaries turned a profit of **₹134.06 Lacs**, though the consolidated bottom line remained impacted by legacy Kratos losses. --- ### **Risk Factors & Mitigation** * **Regulatory Legacy:** A decade-long fee dispute with **SEBI** involving **₹6.08 Crores** was settled in **late 2024**, resulting in a **"No Dues Certificate"** and the release of all frozen assets in **February 2025**. * **Insolvency Implementation:** While the **PPIRP** is approved, the company must maintain **25% Minimum Public Shareholding (MPS)** following the Open Offer (priced at **₹30.00 per share**). * **Operational Gestation:** High-tech medical and energy projects involve long gestation periods and significant capital intensity. * **Market Competition:** The company faces pressure from unorganized players in the diagnostics and paper sectors, mitigated by its focus on **BIS, ISO 9001-2015**, and **CDSCO** certifications.